通过利用第二代RRM2和CHK1抑制剂的协同潜力,针对神经母细胞瘤中的复制应激
Iris H Nelen1,2, Soetkin Leys1,2, Sarah-Lee Bekaert1,2
1Pediatric Precision Oncology Lab (PPOL), Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
Cell death & disease
|February 25, 2026
概括
将RRM2抑制与CHK1抑制剂相结合显示出治疗神经母细胞瘤和肉瘤的前景. 这种新的方法针对复制应激,增强癌细胞死亡,并显示出显著的治疗潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 瘤细胞,特别是神经母细胞瘤 (NB),表现出高复制压力 (RS),并依赖ATR-CHK1信号传递来生存.
- 核酸减少酶M2 (RRM2) 子单元对于DNA合成至关重要,并且已被确定为NB中的新型依赖性,有助于RS耐药性.
研究的目的:
- 评估一种新型RRM2抑制剂,TAS1553,用于直接向核糖缩酶 (RNR) 复合体.
- 在神经母细胞瘤和肉瘤模型中,评估结合RRM2抑制 (TAS1553) 与CHK1抑制剂 (prexassertib,SRA737) 的协同效果.
主要方法:
- 在体外研究使用NB和肉瘤细胞系和瘤.
- 在神经母细胞瘤斑马鱼异种移植模型中的体内疗效评估.
- 评估TAS1553对细胞生长,RS,DNA损伤和亡的影响.
主要成果:
- TAS1553治疗有效地阻碍了细胞生长,并诱导RS,DNA损伤和亡.
- 当将TAS1553与CHK1抑制剂prexasertib和SRA737结合在细胞系,瘤和斑马鱼异种移植模型中时,观察到强烈的协同效应.
- 组合疗法在神经母细胞瘤异种移植模型中表现出显著的体内疗效.
结论:
- 使用TAS1553直接抑制RRM2是一种针对癌细胞的可行策略.
- 结合的RRM2和CHK1抑制显示出强大的协同活性对神经母细胞瘤和肉瘤.
- 这项研究支持TAS1553和SRA737用于神经母细胞瘤和肉瘤治疗的进一步临床前开发.
更多相关视频
10:50Molecular Modulation by Lentivirus-Delivered Specific shRNAs in Endoplasmic Reticulum Stressed Neurons
Published on: April 24, 2021
1.4K
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
1.8K
相关概念视频
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Restarting Stalled Replication Forks
6.5K
DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...
6.5K
DNA Damage can Stall the Cell Cycle
10.2K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
10.2K
DNA Damage Can Stall the Cell Cycle
3.3K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
3.3K
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
